University of Rochester

Neurocrine Biosciences, Inc.

Califia Bio, Inc.

Val S Goodfellow

Harris A Gelbard

Stephen Dewhurst

Torsten R Wiemann

Colin J Loweth

Satheesh Babu Ravula

Jonathan Bryant Grey

Martin W Rowbottom

Warren Stanfield Wade

Brian Dyck

Junko Tamiya

Dongpei Wu

Troy Vickers

Joseph Pontillo

Thong X Nguyen

Mingzhu Zhang

Mehrak Kiankarimi

Sarah Clough

Provided are compounds having an inhibitory effect on Mixed Lineage Kinases. The compounds include substituted pyrrolo[2,3-b]pyridines having Formula IX  Also provided are pharmaceutical compositions, methods of preparing the compounds, synthetic intermediates, and methods of using the compounds, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by Mixed Lineage Kinase inhibition. Also provided are methods of treatment neuropsychiatric disorders which comprise the inhibition of Mixed Lineage Kinases.

Substituted pyrrolo[2,3-b]pyridines as MLK inhibitors

Provided herein are imidazopyridine compounds having an inhibitory effect on mixed lineage kinases (MLKs), methods of their synthesis, and methods of their therapeutic. Also provided are pharmaceutical compositions comprising the compounds and methods of using the compounds and pharmaceutical compositions.

Mixed lineage kinase inhibitors and method of treatments

Provided are compounds having an inhibitory effect on Mixed Lineage Kinases. The compounds include substituted pyrrolo [b]pyridines having Formula IX  Also provided are pharmaceutical compositions, methods of preparing the compounds, synthetic intermediates, and methods of using the compounds, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by Mixed Lineage Kinase inhibition. Also provided are methods of treatment of neuropsychiatric disorders which comprise the inhibition of Mixed Lineage Kinases.

Substituted pyrrolo[2,3-B]pyridines as MLK inhibitors

Provided are compounds having an inhibitory effect on Mixed Lineage Kinases, having a structural Formula, Also provided are pharmaceutical compositions, methods of preparing the compounds, synthetic intermediates, and methods of using the compounds, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by Mixed Lineage Kinase inhibition. Also provided are methods of treatment of neuropsychiatric disorders which comprise the inhibition of Mixed Lineage Kinases.

Provided are compounds having an inhibitory effect on kinases including Mixed Lineage Kinases. Also provided are pharmaceutical compositions, methods of preparing the compounds, synthetic intermediates, and methods of using the compounds, independently or in combination with other therapeutic agents, for treating diseases and conditions that are affected by Mixed Lineage Kinase inhibition. Also provided are methods of treatment of neuropsychiatric disorders that comprise the inhibition of Mixed Lineage Kinases.

Bicyclic heteroaryl kinase inhibitors and methods of use

Melanin-concentrating hormone (MCH) receptor antagonists are disclosed having utility for the treatment of MCH receptor-based disorders such as obesity. The compounds of this invention have the following structure: including stereoisomers and pharmaceutically acceptable salts thereof, wherein n, R, R, R, R, R, and Rare as defined herein. Pharmaceutical compositions containing a compound of this invention, as well as methods relating to the use thereof, are also disclosed.

Melanin-concentrating hormone receptor antagonists and compositions and methods related thereto

Growing community of inventors

Encinitas, CA, United States of America

Val S Goodfellow